Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance

Davita IncTrade
Millicom International Cellular S.A. Common StockTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Millicom International Cellular S.A. Common Stock — how do they compare? Davita Inc trades at $179.99 (market cap $11.62B), while Millicom International Cellular S.A. Common Stock trades at $80.27 (market cap $13.34B). The key difference: Davita Inc and Millicom International Cellular S.A. Common Stock are close in size by market cap, and Millicom International Cellular S.A. Common Stock pays a 3.77% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.

DVATIGO
Market Cap
$11.62B$13.34B
Volume
400,9031,586,684
Sector
HealthMedia
52-Week High
$240.96$104.31
52-Week Low
$103.87$45.81
Typical Hold Time
114 Days0 Days
Enterprise Value
$24.33B$24.38B
Dividend Yield
—3.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $180.70, down 0.59% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 15.43 P/E ratio. The stock shows bullish technical signals with moving averages supporting upward momentum, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent partnership expansion with Humana for value-based kidney care represents significant business development.

DVA presents compelling value with analyst consensus target of $235.67 offering 30% upside potential, supported by Warren Buffett's substantial ownership. Key risks include rising debt-to-asset ratio reaching 65.55% and regulatory pressures in healthcare. The combination of earnings momentum, institutional support, and reasonable valuation creates favorable investment conditions despite margin compression concerns.

Millicom International Cellular S.A. Common Stock

TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.

The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
100% Buy0% Sell
Avg holding period · 114 Days
TIGO
100% Buy0% Sell
Avg holding period · 0 Days

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About Millicom International Cellular S.A. Common Stock

Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.

Read more on TIGO →